Steve Brozak
Stock Analyst at WBB Securities
(0.49)
# 4,196
Out of 5,154 analysts
9
Total ratings
33.33%
Success rate
-13.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $11.49 | +291.64% | 3 | Oct 15, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $1.20 | +400.00% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.39 | +799.28% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $0.95 | +1,692,126.34% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $11.49
Upside: +291.64%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $1.20
Upside: +400.00%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.39
Upside: +799.28%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $0.95
Upside: +1,692,126.34%